Ovejero-Benito María C, Prieto-Pérez Rocío, Llamas-Velasco Mar, Belmonte Carmen, Cabaleiro Teresa, Román Manuel, Ochoa Dolores, Talegón María, Saiz-Rodríguez Miriam, Daudén Esteban, Abad-Santos Francisco
Clinical Pharmacology Department, Hospital Universitario de la Princesa, Instituto Teófilo Hernando, Universidad Autónoma de Madrid (UAM), Instituto de Investigación Sanitaria La Princesa (IIS-IP), Madrid, Spain.
Dermatology Department, Hospital Universitario de la Princesa, Universidad Autónoma de Madrid (UAM), Instituto de Investigación Sanitaria La Princesa (IIS-IP), Madrid, Spain.
Pharmacogenomics. 2017 May;18(7):631-638. doi: 10.2217/pgs-2017-0014. Epub 2017 May 4.
Few studies have evaluated the influence of pharmacogenetics in psoriatic patients treated with etanercept.
MATERIALS & METHODS: We evaluated the association between 124 polymorphisms with the response to etanercept in patients with moderate-to-severe plaque psoriasis at 3 months (n = 78) and 6 months of treatment (n = 68).
The results of the multivariate analysis showed an association between polymorphisms rs13437088 (HLA-B/MICA), rs96844 (MAP3K1), rs2431697 (PTTG1), rs9304742 (ZNF816A) and the response to etanercept at 3 months. Besides polymorphisms rs928655 (GBP6) and rs2546890 (IL12B) were associated to response at 6 months.
Nevertheless, these biomarkers should be validated in large-scale studies before its implementation in clinical practice.
很少有研究评估药物遗传学对接受依那西普治疗的银屑病患者的影响。
我们评估了124个多态性与中重度斑块状银屑病患者在治疗3个月（n = 78）和6个月（n = 68）时对依那西普反应之间的关联。
多变量分析结果显示，多态性rs13437088（HLA - B/MICA）、rs96844（MAP3K1）、rs2431697（PTTG1）、rs9304742（ZNF816A）与3个月时对依那西普的反应相关。此外，多态性rs928655（GBP6）和rs2546890（IL12B）与6个月时的反应相关。
然而，在临床实践中应用这些生物标志物之前，应在大规模研究中对其进行验证。
